Aurora Therapeutics

Aurora Therapeutics, founded in 2026, focuses on developing personalized gene editing therapies. The company has not undergone any notable pivots since its inception. It has established its headquarters in Cambridge, US. Aurora was founded with the backing of a team of seasoned professionals in genetic research.00 mn.Aurora Therapeutics specializes in personalized gene editing solutions targeting rare genetic diseases. The company utilizes advanced CRISPR technology, enabling the rapid and precise customization of gene editing therapies for a multitude of genetic mutations that contribute to rare diseases. This innovative approach addresses a significant unmet medical need, as most existing therapies are incapable of targeting the vast array of rare mutations effectively. Aurora's solutions aim to deliver tailored treatments directly to patients suffering from these conditions, thereby improving therapeutic outcomes.Aurora Therapeutics generates revenue through strategic partnerships and collaborations with healthcare organizations and research institutions engaged in genetic research and therapy development. The business model is focused on B2B transactions, where Aurora provides gene editing technologies and services to these entities. Revenue streams may include licensing agreements for their proprietary gene editing platform, as well as fees for custom gene editing services tailored to specific client needs. These transactions are structured around project-based pricing or retainer agreements that outline the scope of services provided. The company plans to expand its market presence into additional regions in North America and Europe by the end of 2026, aiming to address a broader audience needing tailored genetic therapies.

1. Seed

   Jan 9, 2026

   Amount

   $16M

   Investors

   Locked